Высокоинтенсивный фокусированный ультразвук в лечении рака предстательной железы

Background. High intensity focused ultrasound (HIFU) is a method of delivering acoustic energy to a focal point, thus destroying it and causing coagulation necrosis. Repeating the fires, the whole needed volume of organ can be treated without damaging the adjacent tissue. Objective. To establish the clinical efficacy and safety of HIFU in the treatment of prostate cancer on the basis of the authors’ 3-year experience in applying this technique.

Materials and methods. A total of 101 patients with biopsy-proven prostate cancer (and 2 more patients had only high-grade PIN) have been treated in our clinic using an Ablatherm® device. Seventy-one of them were enrolled in this study. They were followed from sixth months to three years at a regular interval, the follow-up included PSA measurement and control sextant biopsies.

Results. The median PSA nadir 1.5Р3.0 months after treatment ranged from 0.10 (in the low-risk localized prostate cancer group) to 2.50 ng/mL (in patients with a disseminated process). Negative control biopsies were in 75—80% of patients with localized prostate cancer and in 64—75% of the patients with disseminated process. Of all the patients, 91% underwent transurethral resection of the prostate before HIFU treatment. Such combination improved the efficacy of HIFU and reduced the treatment-related morbidity significantly. Grades 2 and 3 stress incontinence was observed in 1.9 and 0.9% of the patients, respectively. No other severe complications were recorded. Erectile function was preserved in 69.94% of the patients.

Conclusion. Our results demonstrated the efficacy and low-associated morbidity of HIFU. HIFU does not exclude other treatment options and is repeatable if needed. HIFU seems to be a valid alternative treatment for patients who are not suitable for radical surgery.

1. Братчиков О.И. Ильченко В.А., Шумакова Е.А. и др. Некоторые аспекты диагностики и лечения рака предстательной железы. Материалы I конгресса РООУ. 4—5 октября 2006 г., Москва.

2. Лопаткин Н.А., Сивков А.В., Аполихин О.И. и др. Рак предстательной железы (компакт-диск). НИИ урологии Минздрава РФ, 2002.

3. Kremkau F.W. Cancer therapy with ultrasound: a historical review. J Clin Ultrasound 1979;7:287—300.

4. Акопян В.Б., Ершов Ю.А. Основы взаимодействия ультразвука с биологическими объектами. М., Изд-во МГТУ им. Баумана; 2005.

5. Chapelon J.Y., Margonari J., Vernier F. et al. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 1992;52:6353—7.

6. Oosterhof G.O.N., Cornel E.B., Smits G.A.H.J. et al. Influence of highintensity focused ultrasound on the development of metastases. Eur Urol 1997;32:91—5.

7. Azzouz Н. HIFU: Local Treatment of Prostate Cancer. EAU-EBU Update Series 2006;4:62—70.

8. Rewcastle J.C. High Intensity Focused Ultrasound for Prostate Cancer: 2006 Technology and Outcome Update. Available from: http://www.hifu.ca/pdf/Rewcastle%202006%20HIFU%20Update.pdf

9. Vallancien G., Prapotnich D., Cathelineau X. et al. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer; feasibility study. J Urol 2004;171(6 Pt 1):2265—7.

10. Chaussy C., Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003;4(3):248—52.

11. Thuroff S., Chaussy C. High-intensity focused ultrasound: complications and adverse events. Molec Urol 2000; 4(3): 183—7; discussion 189.

12. Thuroff S., Chaussy C., Vallancien G. et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003;17(8):673—7.

13. Rebillard X., Gelet A., Davin J.L. et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol 2005;19(6):693—701.

14. Poissonnier L., Gelet A., Chapelon J.Y. et al. Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA <or + 10ng/ml]. Prog Urol 2003;13(1):60—72.

15. Teillac P. et al. Treatment of localized disease. High-intensity focused ultrasound (HIFU). Prostate cancer. 2nd international consultation on prostate cancer. 1999 June 27—29, Paris. p. 306—10.

16. Blana A., Walter B., Rogenhofer S., Wieland W.F. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63(2):297—300.

17. Chaussy C., Thuroff S., Rebillard X., Gelet A. High-intensity focused ultrasound: the insight on the technology. Nat Clin Pract Urol 2005;2(4):191—8.

18. Ablatherm®. High Intensity Focused Ultrasound treatment for localized prostrate cancer. 2006. Available from: www.edap-hifu.com